Our new Cryptocurrency section has arrived! Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValirx Share News (VAL)

Share Price Information for Valirx (VAL)

London Stock Exchange
Share Price: 0.125
Bid: 0.12
Ask: 0.13
Change: 0.00 (0.00%)
Spread: 0.01 (8.33%)
Open: 0.125
High: 0.125
Low: 0.125
Yest. Close: 0.125
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

ValiRx Subscription Raises GBP300,000 For Drug Trial And Development (ALLISS)

Thu, 13th Jun 2019 11:07

(Alliance News) - ValiRx PLC on Thursday said it raised GBP300,000 via subscription for working capital and to progress the clinical trial of its VALL201 cancer drug.

Shares in ValiRx dropped a steep 31% to 0.21 pence in morning trade.

The clinical stage biotechnology company raised the GBP300,000 via the issue of 150,000 shares at 0.2 pence each. The money will be used for "immediate general working capital needs" as well as for the phase 1/2 clinical trial of VAL201, which is intended to treat prostate cancer and "associated metastatic conditions".

Placing proceeds will also help with the development of ValiRx's pre-clinical programmes, Val301 and VAL101, toward the clinic.

In addition to the GBP300,000 from the placing, ValiRx is also expecting proceeds of around GBP150,000 from the sale of an unlisted security as well as a GBP400,000 research and development tax credit from HM Revenue & Customs in July.

Novum Securities Ltd was ValiRx's broker for the placing, and the fee arrangement includes the issues of warrants over 7.5 million shares in ValiRx to Novum, which have an exercise price of 0.2p per share until three years after the warrant issue.

Following admission, ValiRx's enlarged share capital will be 902.6 million shares.

On Monday, ValiRx said it was in advanced discussions with European High Growth Opportunities SF to terminate a subscription agreement. No definitive agreement has yet been made, but ValiRx expects to pay no more than GBP150,000 to European High Growth Opportunities SF to terminate the agreement.

More News

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

14 Oct 19 13:44

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

26 Sep 19 11:43

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

24 Sep 19 12:40

ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints

(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and

10 Sep 19 13:45

ValiRx Granted European Patent Allowance For VAL301 Compound

(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a

1 Aug 19 12:01

Monecor Takes Nearly 6% Holding In Biotechnology Firm ValiRx

(Alliance News) - ValiRx PLC on Tuesday said Monecor London Ltd now holds 5.7% interest in the biotechnology company.Prior to this transaction on Monday, Monecor's holding totalled were

23 Jul 19 16:25

US Grands Patent Claim For valiRx's VAL201 In Metastatic Cancer

(Alliance News) - ValiRx PLC on Wednesday said the US has allowed a patent claim for the use of VAL201 in metastatic cancer.Shares in ValiRx were down 7.1% at 0.21 pence in afternoon trade

26 Jun 19 14:30

ValiRx gets US patent protection for use of VAL201 peptide

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.

26 Jun 19 10:53

ValiRx secures 'substantial amendment' to VAL201 clinical trials

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

20 Jun 19 09:54

ValiRx Subscription Raises GBP300,000 For Drug Trial And Development (ALLISS)

(Alliance News) - ValiRx PLC on Thursday said it raised GBP300,000 via subscription for working capital and to progress the clinical trial of its VALL201 cancer drug.Shares in ValiRx a 31%

13 Jun 19 11:07

ValiRx In Discussions With Investor To End Subscription Agreement (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Monday confirmed it is in advanced discussions with European High Growth Opportunities SF to terminate a subscription agreement.Shares in the clinical

10 Jun 19 09:50

ValiRx Convertible Bond Talks In Advanced Stage; Plans Open Offer (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Wednesday said it is in advanced discussions with European High Growth Opportunities SF to enter a new convertible bond facility and is planning an open in a

5 Jun 19 10:54

ValiRx Extends Talks With Investor Over New Convertible Bond (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has extended the deadline to enter into a new convertible bond with European High Growth Opportunities SF to July 1.The cancer life was

31 May 19 12:04

ValiRx Annual Loss Widens On Higher Costs And Fair Value Losses

LONDON (Alliance News) - ValiRx PLC on Wednesday reported a widened annual loss due to higher costs and losses on the fair value of financial assets.For 2018 the life sciences company, on a

29 May 19 10:41

ValiRx losses widen as it continues to progress drug development

(Sharecast News) - Life science company ValiRx reported a loss before income tax of £4.83m in its final results on Wednesday, widening from the £3.55m loss it posted a year earlier.

29 May 19 10:19

Login to your account

Don't have an account? Click here to register.